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Cancer Therapy: Preclinical
Metformin Amplifies Chemotherapy-Induced AMPK Activation and
Antitumoral Growth
Guilherme Z. Rocha1, Marlia M. Dias1, Eduardo R. Ropelle1, Felipe Osorio-Costa1, Franco A. Rossato2,
Anibal E. Vercesi2, Mario J.A. Saad1, and Jose B.C. Carvalheira1
Abstract
Purpose: Metformin is a widely used antidiabetic drug whose anticancer effects, mediated by the
activation of AMP-activated protein kinase (AMPK) and reduction of mTOR signaling, have become
noteworthy. Chemotherapy produces genotoxic stress and induces p53 activity, which can cross-talk with
AMPK/mTOR pathway. Herein, we investigate whether the combination of metformin and paclitaxel has
an effect in cancer cell lines.
Experimental Design: Human tumors were xenografted into severe combined immunodeficient
(SCID)mice and the cancer cell lines were treated with only paclitaxel or onlymetformin, or a combination
of both drugs. Western blotting, flow cytometry, and immunohistochemistry were then used to char-
acterize the effects of the different treatments.
Results: The results presented herein show that the addition of metformin to paclitaxel leads to
quantitative potentialization of molecular signaling through AMPK and a subsequent potent inhibition of
the mTOR signaling pathway. Treatment with metformin and paclitaxel resulted in an increase in the
number of cells arrested in the G2–M phase of the cell cycle, and decreased the tumor growth and increased
apoptosis in tumor-bearing mice, when compared with individual drug treatments.
Conclusion: We have provided evidence for a convergence of metformin and paclitaxel induced
signaling at the level of AMPK. This mechanism shows how different drugs may cooperate to augment
antigrowth signals, and suggests that target activation of AMPK by metformin may be a compelling ally in
cancer treatment. Clin Cancer Res; 17(12); 3993–4005. 2011 AACR.
Metformin is an oral hypoglycemiant agent used as first-
line therapy for type 2 diabetes, which is now prescribed to
almost 120 million people in the world. There are a large
number of epidemiologic studies indicating that diabetics
have an increased risk of cancer and cancer mortality (1, 2).
Increasing evidence also supports a decreased risk of cancer
mortality associated with metformin use in patients with
type 2 diabetes (3–6). Furthermore, metformin has been
shown to inhibit the growth of cancer cells in vitro and in
vivo (7–12) and, while there are still no randomized control
trials of metformin as a therapy for cancer, there is intri-
guing evidence that metformin may enhance chemother-
apy for established tumors (13, 14).
Metformin has been found to activate AMP-activated
protein kinase (AMPK) signaling (15), and this has become
an important focus of interest in carcinogenesis, because
AMPK has been implicated in the regulation of mTOR
activity, which is frequently activated in cancer (16–20).
AMPK is the downstream component of the tumor sup-
pressor, LKB1, which acts as a sensor of cellular energy
charge, being activated by increasing AMP, coupled with
falling ATP (21). The AMP/LKB1-dependent activation of
AMPK results from pathologic stresses such as heat shock,
hypoxia, glucose deprivation, and metformin administra-
tion (15, 21). AMPK is also activated through Caþ2/calmo-
dulin (CaM)-dependent protein kinase kinase (CaMKK),
which in contrast to that mediated by AMP/LKB1, is
mediated by calcium increases and functions indepen-
dently of AMP (22, 23). Once activated, AMPK phosphor-
ylates acetyl-CoA carboxylase (ACC) and switches on
energy-producing pathways at the expense of energy-
depleting processes (24).
Another direct consequence of AMPK activation is the
inhibition of the mTOR kinase signaling pathway. mTOR
catalytic activity is halted by AMPK activation of the TSC1–
TSC2 complex, which inactivates the Rheb GTPase (25,
26). In addition, mTOR activity is positively regulated by
growth factors and nutrients (amino acids). PI3K/Akt
signaling regulates mTOR through phosphorylation/inac-
tivation of mTOR’s negative regulator, TSC2 (17, 27).
mTOR activation results in the phosphorylation of the
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serine/threonine kinase p70S6K and the translational
repressor eukaryotic initiation factor (eIF) 4E binding
protein (4E-BP1), which have an essential role in regulating
cell growth and proliferation by controlling mRNA transla-
tion and ribosome biogenesis (28).
To achieve normal cell growth and proliferation, it is
critical for cells to have robust antigrowth signaling sys-
tems. AMPK has a major role as an antigrowth signal,
because it is activated by p53, a sensor of DNA damage
stress (29). Recently, the genotoxic stress effect was further
evaluated and it has been suggested that the inhibition of
mTOR activity occurs through the p53-dependent upregu-
lation of sestrins (SESN1 and SESN2) and consequent
activation of AMPK (30). These observations indicate that
metformin acts synergistically with chemotherapeutic
drugs that increase genotoxic stress through a convergent
signaling of metformin-mediated LKB-1/AMPK activation
and chemotherapeutic drug activation of SESNs, culminat-
ing in an increased AMPK activation andmTOR inhibition.
Thus, this study was designed to investigate whether met-
formin potentiates paclitaxel antitumor effects, a well-
known chemotherapeutic drug frequently used in breast
and lung cancer patients (31, 32), and to observe whether
these drugs share common intracellular signal transduction
pathways and to determine whether these signaling sys-
tems modulate each other’s actions in different cancer cell
lineages and in xenografted tumor cells in mice.
Materials and Methods
Antibodies, chemicals, and buffers
All the reagents were from Sigma-Aldrich unless other-
wise specified. Paclitaxel was obtained from Laboratorio
Qumico Farmacêutico Bergamo Ltda. Anti–phospho-
mTOR, anti-mTOR, anti–phospho-p70S6K, anti-p70S6K,
anti–phospho-4E-BP1, anti–4E-BP1, anti–phospho-
AMPKa, anti-AMPKa, anti–b-actin, anti–acetyl-lys379-
p53, anti–phospho-p53, anti–phospho-ACC, anti–caspase
3, anti–cleaved caspase 3, anti-p27, and anti–phospho-Rb
antibodies for immunoblotting were from Cell Signaling
Technology; anti-p53 and anti-SESN2 antibodies for
immunoblotting were from Santa Cruz Biotechnology;
and anti-SESN1 and anti-SESN3 antibodies for immuno-
blotting were from Abcam.
Cell culture
The human breast cancer cell lineMCF-7 (LKB1-positive)
and human lung cancer cell line A549 (LKB1-negative)
were obtained from ATCC. MCF-7 and A549 cells were
cultured in Dulbecco’s Modified Eagle’s Medium contain-
ing 10% FBS with the addition of antibiotics or fungicides.
Both cell lines were maintained at 37C in a humid atmo-
sphere and 5% CO2.
Transfection
A total of 3  105 cells were seeded in a tissue culture
plate in complete growth medium and incubated over-
night. On the day of transfection, 200 pmol of siRNA was
diluted into OPTI-MEM (Life Technologies) and mixed
with 10 mL of Lipofectamine 2000 (Life Technologies)
according to supplier’s protocol. The transfection medium
was then replaced by complete medium and after 24 hours
cells were treated with metformin (10 mmol/L) and pacli-
taxel (1 mmol/L) and incubated for an additional 6 hours.
siRNA for AMPK was 50-AAUUACUUCUGGUGCAG-
CAUAGCGG-30 forward and 50-CCGCUAUGCUGCACCA-
GAAGUAAUU-30 reverse; for SESN1, 50-GAACCUUCUCA-
GAGUGCUUGAACUG-30 forward and 50-CAGUUCAAG-




Cells were seeded at a density of 2 104 cells/well in 24-
well plates containing 1 mL of complete medium in tri-
plicate. Cells were allowed to attach overnight before
treating with the indicated dose of metformin and pacli-
taxel for 24 hours. Subsequently, viable cells were counted
by using trypan blue staining or they were treated with 0.3
mg/mL of MTT for 4 hours and MTT-formazan conversion
was analyzed by spectrophotometry at 570 nm after culture
medium was removed and ethanol was added.
Cell-cycle analysis
Cells were trypsinized, washed in PBS, centrifuged, and
pellets were fixed in 200 mL of 70% ethanol and stored at
20C until use. Cells were centrifuged and pellets resus-
pended in 200 mL of PBS, and 10 mg/mL of RNAse A was
incubated for 1 hour at 37C. Subsequently, cells were
resuspended in propidium iodide solution (0.1% sodium
citrate,0.1%TritonX-100,and50mg/mLpropidiumiodide).
Cell-cycle analysiswas carried out by flow cytometry (FACS-
calibur). Data were analyzed by ModFit LT software.
Translational Relevance
Targeted therapies are being increasingly investigated
as new treatment options in oncology. Metformin is a
widely used antidiabetic drug whose anticancer effects
represent a promising and novel approach for the treat-
ment of cancer. Chemotherapy produces genotoxic
stress and induces p53 activity, which can cross-talk
with AMPK/mTOR pathway through sestrins. We tested
the hypothesis that the combination of metformin and
paclitaxel could show a synergistic effect in cancer cell
lines. The findings presented here suggest that com-
bined treatment is more effective in arresting cells in
the G2–M phase of the cell cycle, decreasing tumor
growth and increasing apoptosis in tumor-bearing mice
through a signaling convergence of metformin and
paclitaxel at the level of AMP-activated protein kinase
(AMPK). Our findings, therefore, show that different
drugs may cooperate to increase antigrowth signals, and
suggests that target activation of AMPK may be an
alternative therapeutic strategy in cancer treatment.
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Complex I oxygen consumption
Measurement of oxygen consumption by MCF-7 and
A549 after treatment for 24 hours with metformin (10
mmol/L), paclitaxel (1 m/mol/L), or the combination of
both drugs was carried out by a Oxygraph equipped with a
Clark-type electrode (Hansatech Instruments Limited) in a
closed chamber equipped with magnetic stirrer and tem-
perature control at 37C. Approximately 2.5 106 of viable
MCF-7 cells/mL, and 4  106 of viable A549 cells/mL,
permeable with 10 mmol/L of digitonin, were added in
2 mL of reaction medium containing 125 mmol/L sucrose,
65 mmol/L KCl, 10 mmol/L HEPES, 2.0 mmol/L K2HPO4,
1.0 mmol/L MgCl2 (pH 7.2), 50 mmol/L EGTA, and com-
plex I substrates (2.0 mmol/L malate, 1.0 mmol/L a-keto-
glutarate, 1.0 mmol/L pyruvate, and 1.0 mmol/L
glutamate). Analyses of oxidative phosphorylation and
respiratory activity of mitochondria were made by sequen-
tial additions of 100 mmol/L ADP, 2 mg/mL chloramphe-
nicol acetyltransferase, 100 nmol/L carbonylcyanide
p-trifluoromethoxyphenylhydrazone, 5 mmol/L succinate,
0.5 mmol/L antimycin, and 200 mmol/L N,N,N0,N0-tetra-
methyl-p-phenylenediamine/ascorbate. The data were
reproduced and calculated by the device’s specific software.
Human tumor xenograft models
Four-week-old male severe combined immunodeficient
(SCID) mice were provided by the State University of Cam-
pinas—Central Breeding Center. Animals were inoculated in
the dorsal region, subcutaneously, with 1  106 A549 cells.
The mice had ad libitum access to food and water. Once
tumors became palpable, tumor volume (V) was calculated
daily by measuring the length (L) and width (W) of the
tumorwith calipers byusing the formula:V¼ [W L (Wþ
L)/2)]  0.52. Each group contained 15 animals.
Treatments began when tumors reached 50 to 100 mm3.
Metformin was given daily by gavage at 500 mg/kg body
weight. Paclitaxel was given once a week by intraperitoneal
(i.p.) injection of 10 mg/kg body weight. All experiments
were approved by the Ethics Committee of the State Uni-
versity of Campinas.
Tissue extracts
Mice were anesthetized with sodium amobarbital (15
mg/kg body weight, i.p.). Tumors were removed, minced
coarsely and homogenized in extraction buffer [1% Triton-
X 100, 100 mmol/L Tris (pH 7.4), containing 100 mmol/L
sodium pyrophosphate, 100 mmol/L sodium fluoride, 10
mmol/L EDTA, 10 mmol/L sodium vanadate, 2 mmol/L
PMSF and 0.1 mg of aprotinin/mL]. The extracts were
centrifuged at 11,000 rpm and 4C and the supernatants
of these tissues were used.
Protein analysis by immunoblotting
Whole tissue extracts and cell pellets were homogenized
in extraction buffer, treated with Laemmli sample buffer
containing 100 mmol/L DTT and heated in a boiling water
bath. For total extracts, similar-sized aliquots (50 mg pro-
tein) were subjected to SDS-PAGE. Proteins were resolved
on 8% to 15% SDS gels and blotted onto nitrocellulose
membranes (Bio-Rad). Band intensities were quantified by
optical densitometry of developed autoradiographs by
using Scion Image software (Scion Corporation).
Immunohistochemistry
To detect Ki-67 and cleaved caspase 3, microwave post-
fixation was carried out by a domestic oven which was
delivered to slides immersed in 0.01 mol/L citrate buffer,
pH 6.0, in two 7-minute doses separated by a 2-minute
break. Sections were then incubated at 4C overnight with
primarymonoclonalmouse anti-human Ki-67 cloneMIB-1
fromDako (diluted 1:100) and anti-cleaved caspase 3 from
Cell Signaling Technology. The slides were then incubated
with avidin–biotin complex LSABþ Kit from Dako Cyto-
mation for 30 minutes followed by the addition of diami-
nobenzidine tetrahydrochloride as a substrate-chromogen
solution. After hematoxylin counterstaining and dehydra-
tion, the slides were mounted in Entellan from Merck.
Terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling assay
Terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling (TUNEL) staining was done by a com-
mercial apoptosis detection kit (Roche), according to the
recommendations of the manufacturer. Analysis and doc-
umentation of results were carried out by a Leica FW4500 B
microscope.
Statistical analysis
Data are presented as mean  SEM of at least 3 inde-
pendent experiments. All groups were studied in parallel
and differences between groups were analyzed by ANOVA,
as appropriate, and Bonferroni post hoc tests for multiple
unpairwise comparisons of means. The level of significance
adopted was P < 0.05.
Results
Metformin activates AMPK and inhibits mTOR in
MCF-7 breast cancer cells and A549 lung cancer cells
To examine the effect of metformin on cancer cell
growth, MCF-7 breast cancer and A549 lung cancer cell
lines were treated with various concentrations of metfor-
min (1–50 mmol/L) for different periods of time (0–8
hours). Metformin treatment resulted in the activation of
AMPK, with increased phosphorylation of AMPKa at Thr-
172 in a time- and dose-dependent manner. Activation of
AMPK is associated with decreased activation of mTOR and
p70S6K, a critical translational pathway for protein synth-
esis (10). Metformin treatment resulted in attenuated
activation of mTOR, as shown by the decreased phosphor-
ylation ofmTOR, p70S6K, and 4E-BP1, in a time- and dose-
dependent manner in treated cancer cells, compared with
untreated cells (Fig. 1A–D).
We also observed the effect of 2-deoxy-D-glucose (2-DG),
another AMPK activator, in both cell lines at various con-
centrations, and for different periods of time. As observed
Metformin Sensitizes Cancer Cells to Paclitaxel
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Figure 1. Metformin and paclitaxel activate AMPK and inhibit mTOR in MCF-7 and A549 cells. MCF-7 cells were treated (A) with 10 mmol/L metformin
for the indicated time and (B) for 6 hours with the indicated doses. The lysates were immunoblotted (IB) with the indicated antibodies. A549 cells were
treated (C) with 10 mmol/L metformin for the indicated time and (D) for 6 hours with the indicated doses. The lysates were immunoblotted with the indicated
antibodies. MCF-7 cells were treated (E) with 1 mmol/L paclitaxel for the indicated time and (F) for 6 hours with the indicated doses. The lysates were
immunoblotted with the indicated antibodies. A549 cells were treated (G) with 1 mmol/L paclitaxel for the indicated time and (H) for 6 hours with the indicated
doses. The lysates were immunoblotted with the indicated antibodies. Data are representative of at least 3 experiments.
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for the metformin treatment, 2-DG led to activation of
AMPK and inactivation of the mTOR signaling pathway
(Supplementary Fig. S1A–D).
A549 lung cancer cell line is negative for LKB1 and recent
reports have shown that LKB1 deficiency in hepatocytes
impairs metformin action (33). However, in this study we
show that AMPK activation in A549 cells after metformin
treatment is independent of LKB1 and is dose-responsive,
starting from 1 to 100 mmol/L with ACC phosphorylation
and mTOR and p70S6K inactivation (Supplementary
Fig. S2). The same pattern of AMPK and ACC activation
and mTOR and p70S6K inactivation is seen on MCF-7 cell
line, which is LKB1 normal (Supplementary Fig. S2).
Paclitaxel activates AMPK and inhibits mTOR in
MCF-7 breast cancer cells and A549 lung cancer cells
To investigate the mechanisms underlying the antipro-
liferative effects of paclitaxel, we characterized the effects of
paclitaxel on AMPK and the mTOR pathway. As recently
reported, genotoxic stress increases the amount of SESNs,
and this effect leads to AMPK activation (30). Our results
show that paclitaxel treatment increased the acetylation of
p53 at Lys-379, the phosphorylation of p53 at Ser 15,
which are known markers of genotoxic stress (34, 35),
and the amount of SESN1, SESN2, and SESN3 in a time-
and dose-dependent manner in both cell lines. Paclitaxel
treatment also resulted in increased phosphorylation of
AMPKa at Thr-172, in a time- and dose-dependentmanner.
The increased activation of AMPK led to inactivation of
mTOR as evidenced by diminished phosphorylation of
mTOR, p70S6K, and 4E-BP1 also in a time- and dose-
dependent manner (Fig. 1E–H).
Effect of combined treatment of AMPK activators
and paclitaxel on cancer cell lines
We next sought to determine the effects of the combined
treatment of AMPK activators with paclitaxel. In MCF-7
cells, as shown in Figure 2A, paclitaxel treatment led to a
higher increase in acetyl-Lys 379 p53 than metformin or 2-
DG treatment, as well as an increase in the amount of
SESN2 (Fig. 2B). This increase in SESN2 in paclitaxel-
treated cells was followed by an increase in the phosphor-
ylation of Thr-172 of AMPK (Fig. 2C) and inhibition of
mTOR (Fig. 2D), p70S6K (Fig. 2E), and 4E-BP1 (Fig. 2F),
when compared withmetformin or 2-DG treatments alone.
Even though metformin or 2-DG treatment do not increase
SESN2 (Fig. 2B), we observe an increase in AMPK phos-
phorylation (Fig. 2C) and inhibition of mTOR (Fig. 2D),
p70S6K (Fig. 2E), and 4E-BP1 (Fig. 2F), when compared
with vehicle-treated cells. In A549 cells, we also observed
an increase in acetyl-Lys379 p-53 and in the amount of
SESN2 only in the paclitaxel-treated cells (Fig. 2G and H),
when compared with control and metformin and 2-DG
alone, and this was correlated with an increase in the Thr-
172 phosphorylation of AMPK and decrease in the activa-
tion of mTOR, p70S6K, and 4E-BP1 when compared with
control. Once again, metformin and 2-DG treatments did
not increase SESN2 (Fig. 2H) but they were able to increase
AMPK phosphorylation (Fig. 2I) and inhibit mTOR
(Fig. 2J), p70S6K (Fig. 2K), and 4E-BP1 (Fig. 2L), when
compared with vehicle-treated cells.
Metformin and paclitaxel inhibit cell viability
To examine the effects of metformin and paclitaxel on
cancer cell growth, we treated MCF-7 and A549 cell lines
with metformin or paclitaxel alone or in combination
and cell viability was determined. As shown in Figure 3A
and B, both metformin and paclitaxel inhibited cell
viability, as related to vehicle-treated cells. The metformin
treatment was statistically significant at 10 mmol/L for
the 48- and 72-hour treatment (Fig. 3A) in MCF-7 cells
and that a 1 mmol/L dose of metformin was capable of
reducing A549 cells proliferation by approximately 20%
to 30% for both the 48- and 72-hour treatments. The
paclitaxel treatment was effective only at the dose of 10
nmol/L for both 48- and 72-hour treatments (Fig. 3B).
Figure 3C and D shows that in the combined treatment
metformin potentiates paclitaxel action on MCF-7
(Fig. 3C) and A549 (Fig. 3D) cells, as a dose of
1 nmol/L of paclitaxel is statistically different from the
metformin and vehicle-treated cells for both the 48- and
72-hour treatments. At 10 nmol/L of paclitaxel, metfor-
min does not further potentiate paclitaxel treatment on
MCF-7 cells. However, in A549 cells, we observed that
at the 48-hour treatment metformin (10 mmol/L) and
10 nmol/L paclitaxel is more effective on reducing cell
growth than paclitaxel-alone treatment (Fig. 3D). We
then analyzed cell viability by trypan blue staining of
both cell lines (Fig. 3E), which showed that both met-
formin and paclitaxel inhibited cell viability, as related to
vehicle-treated cells, and the combined treatment was
more effective than either treatment alone.
Effect of metformin, 2-DG, and paclitaxel on cell cycle
To evaluate the mechanism of growth inhibition by
metformin, 2-DG, and paclitaxel, the cell-cycle profile
was analyzed by flow cytometry after treatment with met-
formin, 2-DG, or paclitaxel alone, or the combination of the
drugs. Vehicle treatment presented the majority of cells in
theG1 phase of the cell cycle (MCF-7, 68.8%; A549, 71.2%),
a small part in theG2–Mphase (MCF-7, 12.4%;A549 8.6%)
and the rest of the cells were found to be in the S-phase
(MCF-7 18.8%, A549, 20.2%). 2-DG treatment resulted in a
slight increase in cells in G1 phase arrest (MCF-7, 72.1%;
A549, 77.4%), with a decrease in S-phase (MCF-7, 15.3%;
A549, 15.4%) and no significant alteration in G2–M phase
(MCF-7, 12.6%; A549, 7.2%). Metformin treatment
resulted in an increase in the number of cells in the G1
phase (MCF-7, 80.6%; A549, 81.2%) with almost similar
number of cells in the G2–M phase of MCF-7 cells (MCF-7,
9.5%; A549, 8.7%) and a reduction in the number of cells in
the S-phase in both cell lines (MCF-7, 9.9%; A549, 10.2%).
Metformin combined with 2-DG (MET þ 2-DG) treatment
resulted in a decrease in the number of cell in G1 phase
(MCF-7, 53.5%; A549, 52.1%), and increase in cells in the
G2–M phase arrest (MCF-7, 33%; A549, 35.3%) and a
Metformin Sensitizes Cancer Cells to Paclitaxel
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Figure 2. Effect of combined treatment with 2-DG, metformin, and paclitaxel on MCF-7 and A549 cells. Cells were treated with 10 mmol/L metformin,
10 mmol/L 2-DG, and 1 mmol/L paclitaxel for 6 hours, and cells were prepared as described in Materials and Methods. The lysates of MCF-7 cells were
immunoblotted (IB) with (A) acetyl-Lys-379 p53 and p53, (B) SESN2 and b-actin, (C) pAMPKa and AMPKa, (D) pmTOR and mTOR, (E) pp70S6K and
p70S6K, and (F) p4E-BP1 and 4E-BP1. The lysates of A549 cells were immunoblotted (IB) with (G) Acetyl-Lys-379 p53 and p53, (H) SESN2 and b-actin,
(I) pAMPKa and AMPKa, (J) pmTOR and mTOR, (K) pp70S6K and p70S6K, and (L) p4E-BP1 and 4E-BP1. Data (mean  SEM; n ¼ 3 experiments in triplicate)
are presented as relative to control. *, P  0.05 vs. control; #, P  0.05 vs. paclitaxel; z, P  0.05 vs. metformin.
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Figure 3. Metformin (MET) and paclitaxel (PTX) inhibit cell viability. A, cell viability of MCF-7 and A549 cells treated with increasing doses of metformin
for 48 or 72 hours measured by MTT assay. B, cell viability of MCF-7 and A549 cells treated with increasing doses of paclitaxel for 48 or 72 hours measured by
MTT assay. Data (mean  SEM; n ¼ 3 experiments in triplicate) are presented as relative to vehicle. *, P  0.05 vs. vehicle. C, cell viability of MCF-7
cells treated with increasing doses of paclitaxel or associated with metformin (10 mmol/L) for 48 or 72 hours measured by MTT assay. D, cell viability of A549
cells treated with increasing doses of paclitaxel or associated with metformin (10 mmol/L) for 48 or 72 hours measured by MTT assay. Data
(mean SEM; n¼ 3 experiments in triplicate) are presented as relative to vehicle. *,P 0.05 vs. vehicle; #,P 0.05 vs. metformin. E, cell viability ofMCF-7 and
A549 cells treated with metformin (10 mmol/L), paclitaxel (1 umol/L), or a combination, as measured by trypan blue staining. Cells were treated for
48 hours with respective drugs. Data (mean  SEM; n ¼ 3 experiments in triplicate) are presented as relative to vehicle. *, P  0.05 vs. vehicle; #, P 
0.05 vs. metformin; z, P  0.05 vs. paclitaxel. F, cell-cycle analysis of MCF-7 and A549 cells treated with metformin (10 mmol/L), paclitaxel (1 mmol/L), or a
combination, as measured by flow cytometry (FACScalibur). Cells were treated for 24 hours with respective drugs. G, MCF-7 and A549 cells were treated
with the indicated drugs for 24 hours and cell lysates were immunoblotted (IB) with the indicated antibodies. H, complex I oxygen consumption rates of
MCF-7 and A549 cells treated for 24 hours with metformin (10 mmol/L), paclitaxel (1 mmol/L), or a combination, as measured by a Oxygraph equipped with
Clark-type electrode. Data (mean  SEM; n ¼ 3 experiments) are presented as relative to vehicle. *, P  0.05 vs. vehicle; z, P  0.05 vs. paclitaxel.
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decrease in cells in S-phase (MCF-7, 13.4%;A549, 12.6%)as
related to vehicle-treated cells. Paclitaxel treatment, as
expected, caused an increase in the number of cells in the
G2–M phase (MCF-7, 21.5%; A549, 18.8%) with a reduc-
tion in the number of cells in the G1 phase (MCF-7, 64%;
A549, 64.7%) and in the S-Phase (MCF-7, 14.5%; A549,
16.5%) in both cell lines (Fig. 3F).
The combined treatment of 2-DG and paclitaxel, of
metformin and paclitaxel and the triple therapy resulted
in a synergistic effect of G2–M cell-cycle arrest. Cells treated
with 2-DG and paclitaxel showed a reduction in G1 phase
(MCF-7, 57.1%; A549, 60.4%), there was no significant
alteration in the number of cells in S-phase (MCF-7, 15.1%;
A549, 16.9%); however, there was an increase in G2–M
phase (MCF-7, 27.8%; A549, 22.7%) compared with either
treatment alone. Cells treated with metformin and pacli-
taxel showed a reduction in G1 phase arrest, compared with
either treatment alone (MCF-7, 54.6%; A549, 45.5%). This
treatment resulted inno significant alteration in thenumber
of cells in the S-phase comparedwith either treatment alone
(MCF-7, 13.5%; A549, 12.8%). Additionally, when we
analyzed theG2–Mphase,weobserveda significant increase
in the number of cells in this phase in the metformin
combined with paclitaxel treatment, as compared with
either treatment alone (MCF-7, 31.9%; A549, 41.8%).
Finally, the triple therapy resulted in a decrease in the
number of cells in G1 phase as compared with MET þ 2-
DG treatment or paclitaxel treatment alone (MCF-7, 40.9%;
A549, 39.7%), a slight decrease in the number of cells in S-
phase (MCF-7, 10.9%; A549, 12.1%) and a significant
increase in the number of cells in G2–M phase (MCF-7,
48.1%; A549, 48.2%). Thus, Figure 3F shows an increase in
cell-cycle arrest in the G2–M phase, during the combined
treatment of MET+2-DG, 2-DG and paclitaxel, metformin
and paclitaxel, and the triple therapy and a decrease in the
G1 phase, indicating that cells submitted to these combined
treatments were not further undergoing division.
We then examined the protein levels of caspase 3 and
cleaved caspase 3, of cyclin D1, of p27, and of phosho-Rb
in the cells. After 24 hours, caspase 3 was slightly decreased
in the metformin and paclitaxel treatments and notably
reduced in both cell lines treated with the combination of
metformin and paclitaxel (Fig. 3G). Cleaved caspase 3 was
slightly increased with metformin or paclitaxel treatments,
and strongly increased in metformin and paclitaxel com-
bined treatment after 24 hours in both cell lines (Fig. 3G).
Cyclin D1 levels were only reduced inmetformin treatment
in both cell lines (Fig. 3G). p27 expression was increased in
metformin treatment whereas phosphorylation of Rb was
reduced in metformin treatment (Fig. 3G).
Cancer cell metabolism is unaffected by paclitaxel and
hampered by metformin
To determine whether metformin, paclitaxel, or the
combined treatment affect cancer cell metabolism we ana-
lyzed their effects on mitochondrial complex I oxygen
consumption in MCF-7 and A549 cell lines. Metformin
decreased complex I oxygen consumption by 58% in MCF-
7 and by 92% in A549, whereas paclitaxel had a modest
effect in both cell lines (Fig. 3H). The combined treatment
showed no significant difference from the metformin treat-
ment alone (Fig. 3H).
AMPK is implicated in the synergistic effect of
metformin and paclitaxel
Figure 4A and B shows that p53 is activated with pacli-
taxel treatment and that further stimulation with metfor-
minþ paclitaxel, 2-DGþ paclitaxel (double therapy), or a
combination of metformin þ 2-DG þ paclitaxel (triple
therapy) does not increase its activation. The same pattern
is seen in SESN2 expression.On the contrary, AMPK shows
a further increase in activation after double or triple
therapies compared with paclitaxel only and vehicle treat-
ments. Additionally, mTOR and its direct substrates
p70S6K and 4EBP-1 are inhibited with paclitaxel treat-
ment and further inhibition is observedwith the double or
triple treatments.
To further evidence the role of AMPK and SESNs in the
combination treatment, we treated MCF-7 and A549 cells
with siRNA toAMPKand to SESN1andSESN2andanalyzed
SESN1 and SESN2 expressions and AMPK, mTOR, p70S6K,
and 4E-BP1 phosphorylation. Figure 4C and D show that
treatment with SESN1 and SESN2 siRNA dampers SESN1
and SESN2 expressions, respectively, and reduces AMPK
phosphorylation, with an increase in mTOR, p70S6K, and
4E-BP1 phosphorylation. Treatment with AMPK siRNA
doesnot reduce SESN1or2 expressionsbut abolishesAMPK
phosphorylation and expression, which increases mTOR,
p70S6K, and 4E-BP1 phosphorylation.
Thus, these results clearly show an essential role for SESN
and AMPK in the activation of AMPK and inhibition of
mTOR, respectively, after the combined treatment of met-
formin and paclitaxel.
The effect of metformin and paclitaxel on A549 tumor
growth in SCID mice
Xenografted SCID mice were treated with control vehi-
cle, metformin, paclitaxel, or metformin and paclitaxel.
Treatments began when the tumors presented an average
size of 50 mm3 and tumor growth rate was measured
daily after the beginning of the treatment. Figure 5A
shows that metformin and paclitaxel is clearly more
effective in reducing tumor growth, as compared with
either paclitaxel alone, metformin alone, or the control.
For the entire experiment, the animals treated with com-
bination of metformin and paclitaxel presented almost
no tumor growth, with the final tumor volume of 71 mm3
being very close to the tumor volume at the beginning of
the treatment, as compared with the final volumes of the
control (377 mm3), metformin (203 mm3), and pacli-
taxel (137 mm3) as shown in Figure 5B. We observed that
2-DG and paclitaxel combination yielded similar results
to metformin and paclitaxel combination. However, we
did not observe an additive effect with the triple therapy
when compared with the double therapy (Supplementary
Fig. S3A and B).
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The reduced tumor growth following metformin and
paclitaxel treatment is due to the reduced proliferation
of tumor cells, as shown by Ki-67 staining and quantifica-
tion (Fig. 5C and D) and increased apoptosis, as quantified
by TUNEL staining (Fig. 5E and F) and cleaved caspase 3
staining (Fig. 5G and H). In the control group, Ki-67–
positive cells were 25.5% (2.8) of the total, in metformin
these cells were 13.4% (1.1), whereas in paclitaxel these
cells were 10.8% (1.2) and metformin and paclitaxel
presented 7.2% (0.4) Ki-67–positive cells (Fig. 5C and
D). The results of the TUNEL staining experiments show
that the control group presented a 9.5% (1.1) apoptosis,
whereasmetformin apoptosis was 16.7% (4.5), paclitaxel
apoptosis was 31.8% (1.8), andmetformin and paclitaxel
apoptosis was 35.9% (4.8) (Fig. 5E and F). Similarly, in
the cleaved caspase 3 staining experiments, the control
group presented a 6.5% (1.0) positive cells, whereas
metformin presented 22.3% (0.8) positive cells, pacli-
taxel presented 27.4% (2.1) positive cells, andmetformin
and paclitaxel combined presented 39.9% (3.6) cells
positive for cleaved caspase 3 (Fig. 5G and H). These data
indicate a reduced proliferation and increased apoptosis in
the combined treatment and are consistent in showing that
there is a significant advantage in the use of combination
treatment with metformin and paclitaxel, as compared
with treatment with either agent alone.
Effect of metformin, paclitaxel, and metformin and
paclitaxel treatment on AMPK and the mTOR pathway
in A549 xenografts
As treatment with metformin and paclitaxel inhibited
tumor growth, we sought to determine the AMPK/mTOR
pathway activation status in the tumor tissue of animals
treated with metformin, paclitaxel, and the combination of
metformin and paclitaxel. Figure 6A shows that both
treatments with paclitaxel resulted in a higher acetylation
of Lysine 379 of p-53 and increased quantity of SESN2, as
compared with control or metformin (Fig. 6B). The phos-
phorylation of AMPK at Thr172 was also higher in the
metformin and paclitaxel treatment, when compared with
paclitaxel alone, metformin alone, or control (Fig. 6C).
Both treatments with paclitaxel and metformin also acti-
vated AMPK, as compared with the control. Similarly,
phosphorylation of mTOR (Fig. 6D), and its direct sub-
strates p70S6K (Fig. 6E) and 4E-BP1 (Fig. 6F), were reduced
following metformin and paclitaxel treatments.
Discussion
In this study, we show that the combination of metfor-
min and paclitaxel has a major antitumor effect in vivo and
induces massive cell-cycle arrest in vitro. These effects are
correlated with a potent activation of AMPK. Our results
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Figure 4. AMPK involvement in the synergistic effect of metformin (MET) and paclitaxel (PTX). A, MCF-7 cells were treated with paclitaxel alone (1 umol/L), with
metformin/paclitaxel (10 mmol/L/1 mmol/L), with 2-DG/paclitaxel (10 mmol/L/1 mmol/L), or the triple therapy for 6 hours. The cell lysates were then
immunoblotted with the indicated antibodies. B, A549 cells were treated with paclitaxel alone (1 mmol/L), with metformin/paclitaxel (10 mmol/L/1 umol/L), with
2-DG/paclitaxel (10 mmol/L/1 mmol/L), or the triple therapy for 6 hours. The cell lysates were then immunoblotted (IB) with the indicated antibodies. C, MCF-7
cells were transfected with siRNA for AMPKa, for SESN1, or for SESN2, and than treated with metformin/paclitaxel (10 mmol/L/1 mmol/L) for 6 hours. The cell
lysates were then immunoblotted with the indicated antibodies. D, A549 cells were transfected with siRNA for AMPKa, for SESN1, or for SESN2, and than
treated with metformin/paclitaxel (10 mmol/L/1 mmol/L) for 6 hours. The cell lysates were then immunoblotted with the indicated antibodies.
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Figure 5. Metformin (MET) and paclitaxel (PTX) synergize in vivo to reduce A549 tumor growth. A549 cells (1.0  106) were injected subcutaneously
into the flank of SCID mice. Once the tumor reached 50 to 100 mm3, treatments were initiated, as indicated in Materials and Methods. Data are presented
as mean  SEM. A, tumor growth was measured daily after beginning treatment. B, tumor volume after 3 weeks of treatment. C, representative
microphotograph of Ki-67 staining on tumor sections (arrows indicate positive Ki-67 staining). D, graph of percentage of Ki-67–positive cells per field;
4 fields per tumor section; mean  SEM. E, representative microphotograph of TUNEL staining on tumor sections. F, graph of percentage of TUNEL-positive
nuclei of cells per field; 4 fields per tumor section; mean  SEM. G, representative microphotograph of cleaved caspase 3 staining on tumor sections.
H, graph of percentage of cleaved caspase 3–positive nuclei of cells per field; 4 fields per tumor section; mean  SEM. *, P  0.05 vs. control; #, P  0.05 vs.
paclitaxel; z, P  0.05 vs. metformin.
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show that metformin, which induces a moderate decrease
in ATP levels (36), is able to produce molecular activation
of AMPK and inactivation of mTOR signaling in breast and
lung cancer cells, whereas paclitaxel, through activation of
p53 and SESNs, yields similar effects to metformin. Com-
bined treatment with metformin and paclitaxel leads to a
quantitative increase in AMPK activation and a drastic
reduction of molecular signaling through the mTOR path-
way. Likewise, the combination of paclitaxel with 2-DG,
which like metformin, leads to intracellular ATP depletion
(37, 38), severely inhibited the mTOR signaling pathway.
It was initially shown that metformin was capable of
reducing proliferation in different types of cancer including,
prostate, colon, andbreast cancer cell lines. Subsequently, in
vivo experiments with metformin resulted in tumor growth
inhibition of up to 55% (12, 39). In accordance with these
data,we herein show thatmetformin treatment resulted in a
reduction of A549 and MCF-7 cell viability and a decreased
tumor volume (approximately 50%) of A549 tumor when
xenografted in SCIDmice. These effects were paralleled by a
decrease in the central regulator of cell growth and survival,
mTOR signaling pathway, as measured by p70S6K and
4EBP-1 phosphorylation.
The mechanisms by which cells protect their genetic
material during genotoxic stress include the alert of check-
point proteins and arrest of cell growth and proliferation
(40, 41). The major cellular stress-sensing molecule is p53,
which halts cell growth and proliferation by increasing
SESNs, thus leading to activation of AMPK and inhibition
ofmTOR(29, 30).Herewe show that paclitaxel induces p53
activation in the cancer cells and activates AMPK. AMPK
activation resulted indecreasedmTORpathway activity; this
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Figure 6. Metformin (MET) and paclitaxel (PTX) activate AMPK and inhibit mTOR in vivo. Mice bearing A549 xenografts were treated with only metformin
or paclitaxel, or a combination, as described in Materials and Methods. The A549 tumor lysates were immunoblotted (IB) with (A) acetyl-Lys-379 p53
and p53, (B) SESN2 and b-actin, (C) pAMPKa and AMPKa, (D) pmTOR and mTOR, (E) pp70S6K and p70S6K, and (F) p4E-BP1 and 4E-BP1. Data (mean 
SEM; n ¼ 8) are presented as relative to control. *, P  0.05 vs. control; #, P  0.05 vs. paclitaxel; z, P  0.05 vs. metformin.
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Intracellular interactions between different signaling
systems may function as mechanisms for enhancing or
counter-regulating signaling pathways. In the case of
metformin, the cross-talk with paclitaxel-induced signal-
ing pathways resulted in direct interactions between these
drug-induced signaling systems at the level of AMPK.
Simultaneous treatment with both drugs led to increased
phosphorylation of AMPK and a drastic reduction of
mTOR signaling pathway. Furthermore, there was no
increase of the effects of the combination of metformin
and paclitaxel compared with only metformin on tumor
cell metabolism. These results suggest that the positive
cross-talk between metformin and paclitaxel-induced sig-
naling was due to additive effects on AMPK activation.
Further inhibition of mTOR pathway with the triple
therapy does not change the antineoplastic effect of
metformin and paclitaxel combination.
The mTOR pathway is a crucial pathway, downstream of
several growth factor receptors including epidermal growth
factor, platelet-derived growth factor, KIT, and insulin like
growth factor I receptor, which coordinate tumor growth
(42, 43). The deregulated mTOR pathway is very frequent
in human cancer. These alterations include mutational
activation of the p110a subunit of phosphoinositide 3-
kinase (PI3K), loss of PTEN function, overexpression of
PI3K, Akt, eIF4E, and p70S6K, as well as inactivation of
tuberous sclerosis 1 or 2 (42, 43). It was also established
that the mTOR pathway can be inactivated by AMPK (44),
which acts through a PI3K-independent mechanism.
The susceptibility of cancer cells to PI3K inhibitors is
highly determined by the presence of mutations in com-
ponents of the PI3K/Akt/mTOR pathway (45). In contrast,
our results showed that a drastic reduction of the mTOR
pathway, elicited by the combination of metformin and
paclitaxel, yields decreased cell viability in both MCF-7,
which has a mutational activation of the PI3K catalytic
subunit, and A549 cells, which does not harbor genetic
alterations in the PI3K/Akt/mTOR pathway. As the mTOR
pathway is essential to cell metabolism and growth, and
delayed mitosis induced by paclitaxel is associated with a
reduction in gene transcription, our data suggest that the
cancer cells may be "pathway addicted," independently of
harboring a mutation in the PI3K/Akt/mTOR pathway
during paclitaxel-induced cell-cycle arrest. It is interesting
to note that the susceptibility of cancer cells to metformin
and paclitaxel combination occurred in a LKB1 indepen-
dent manner. These data are in accordance with Sanli and
colleagues (46) that recently showed that metformin can
activate AMPK, probably through action of a metabolite
derived from complex I inhibition. Thus, our data suggest
that metformin antineoplastic effects are effective even
when LKB1 is suppressed.
Toxicity elicited by paclitaxel has been linked to irrever-
sible tubulin polymerization, a cell-cycle block at the meta-
phase–anaphase transition, and cell death (47, 48). On the
contrary, in addition to the metabolic activity of AMPK,
there is growing evidence that AMPKhas a crucial role in the
establishment of cell division, and it has been suggested that
AMPK may be essential in the coordination between the
sensing of energy resources and genome division (49, 50).
Our results show that the combination of metformin and
paclitaxel has an additive effect on cell viability and, in
accordancewith aprevious study that combined2 activators
of AMPK, metformin and 2-DG, we observed a compelling
accumulation of cells in G2–M (36). As gene transcription is
silenced during mitosis and paclitaxel plus metformin
induced a more prolonged division, our results suggest that
this event leads to a greater decrease in cell viability.
In conclusion, we observed a convergence of paclitaxel-
and metformin- induced signaling at the level of AMPK.
This mechanism illustrates how different drugs may coop-
erate to augment antigrowth signals, suggesting that target
activation of AMPK bymetforminmay be a compelling ally
in cancer treatment.
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